The prevention, detection & control strategies & technical guidance that we develop are based on robust science, generated through extensive, collaborative research, & evaluated by a broad network of experts
2/
@WHO works with scientists, clinical and public health professionals, people affected by public health challenges, across the world
3/
@WHO works with many different technical disciplines from different settings, avoiding conflicts of interest. WHO bases its guidance on critical reviews all the available research.
4/
For new 🦠, it takes time for research to be conducted, so we draw experience from related infections, & reach out to researchers to access new data asap. Where there are gaps, we work w partners to develop research agendas for everything from epi to R&D (@rd_blueprint)
5/
@WHO coordinates international technical networks, which have been working together for decades on various pathogens, across a range of technical areas, from outbreaks to pandemics.
These networks are expanded & strengthened all the time.
6/
@WHO relies on the expertise of guideline development groups who review all of the research and develop the guidance
Guidance is not based on one study, one discipline
7/
@WHO works with patient and civil society groups, implementers, and others to ensure guidance is practical and meets the highest ethical standards.
8/
@WHO's guidance (on all topics) is reached through consensus based on existing science, benefits and harms as well as other considerations such as feasibility and acceptability, values & preferences of affected groups & cost.
9/
@WHO guidance development is based on:
➡️evidence generation
➡️evidence synthesis & critical appraisal
➡️recommendation writing
We continue to review new evidence & update guidance as necessary
Vaccination remains a critical tool for preventing the serious impacts of #COVID19, especially in those at high risk of severe disease - including older adults, individuals with chronic or immunocompromising conditions, pregnant women, and health and care workers.
A number of recent studies continue to demonstrate the impact #COVID19 vaccines have had in preventing death and disability from both acute COVID-19 and increasingly from Post COVID-19 Condition (PCC or #LongCOVID) & more research is needed. However...
Despite not being in the news, #COVID19 has not gone away. @WHO continues to work with all countries on surveillance, reporting & risk assessments of circulating variants (JN.1, KP.2, KP.3…) & their impact.
Yes, the impact of COVID is far less than it was in a few years ago, but we can’t become complacent: Recent vaccination coverage in at risk groups is poor, there are ⬆️ trends in hospitalisations in a number of countries, the virus continues to evolve…
… COVID does not circulate with predictable seasonality, our understanding of acute and long term effects (#LongCOVID) is still weak, there is little effort to prevent the spread. Prevention of infection remains impt even with the overall impact of #COVID19 lower than 20-22, etc
An integral component of @WHO’s overall global strategy for #influenza pandemic preparedness activities is the development of candidate vaccine viruses (CVVs) representing influenza viruses of zoonotic and pandemic risk.
Selection and development of #influenza candidate vaccine viruses (CVVs) are the first steps towards timely vaccine production, when needed…
Due to the evolving nature of influenza viruses, the genetic and antigenic characteristics of contemporary zoonotic influenza A viruses and development of CVVs for pandemic preparedness are summarized and published twice a year ().who.int/teams/global-i…
🧵Lots of interest in #H5N1 in 🇺🇸 so wanted to provide a little background on @WHO’s work in #flu (For latest in US see: @CDCgov @USDA @US_FDA)
And some info on the H5N1 flu vaccine pipeline in humans (note, we don’t need this yet, but I’m getting a lot of questions about this)
@WHO’s work in #flu spans >7 decades with the Global Influenza Surveillance and Response System (GISRS) who.int/initiatives/gl…
GISRS is currently composed of:
152 WHO National Influenza Centers in 130 Member States
7 WHO Collaborating Centers for Influenza and
12 WHO H5 Reference Laboratories who.int/images/default…
For the last few years, @WHO and @CERN have been developing a risk assessment tool to estimate indoor airborne transmission of #SARSCoV2 to better advise on risk mitigation measures for #COVID19.🧵
Note: The risk assessment tool itself has been online for more than a year, helping our member states and partners reduce the risks of airborne transmission indoors.
Many use today as a day to mark significance in the @COVID19 pandemic.
I welcome any way in which we can raise attention to COVID-19, to remember our loved ones lost-and still losing- but also to ensure that we continue to act to tackle the current threat of COVID-19.
It was the day, 4 years ago, the Director-General of @WHO @DrTedros characterized #COVID19 as a pandemic. I remember that day vividly...because it was significant in the lives of everyone on the planet and in mine personally…
But let's accurately mark history here: it's not the day @WHO "declared" a pandemic.
For me, what is heartbreaking is that this day-arguably-marks when the world woke up to the threat of #COVID19, when that awakening should have been at least 6 weeks earlier when DG declared…